On this page
TNNI3
troponin I3, cardiac type
The TNNI3 gene provides instructions for cardiac troponin I, a protein exclusively found in heart muscle that is essential for regulating heart contractions and relaxation. TNNI3 plays a critical role in the normal function of the heart by coordinating the contraction and relaxation cycles of cardiac muscle.
TNNI3 is located on the long (q) arm of chromosome 19, at band 19q13.42. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 19 in the library →Overview
The TNNI3 gene encodes cardiac troponin I (cTnI), a protein vital for the proper functioning of the heart muscle. This protein is exclusively expressed in the heart and is a key component of the troponin complex, which regulates muscle contraction. The coordinated contraction and relaxation of cardiac muscle are fundamental for the heart's ability to pump blood effectively throughout the body [PMID:18451877].
Disruptions in the TNNI3 gene can lead to various cardiac conditions, primarily cardiomyopathies, which affect the heart muscle's structure and function. These conditions can impair the heart's ability to pump blood, potentially leading to serious health complications. Understanding the TNNI3 gene's role is therefore important for diagnosing and managing these inherited heart disorders.
What the gene does
The TNNI3 gene provides the blueprint for cardiac troponin I, a protein integral to the troponin complex within cardiac muscle cells. This complex, along with calcium ions, orchestrates the precise contraction and relaxation of the heart [PMID:18451877]. Cardiac troponin I specifically acts as an inhibitory component, preventing muscle contraction in the absence of appropriate signals.
Within the sarcomere, the fundamental unit of muscle contraction, thick and thin protein filaments interact to generate force. The troponin complex is situated on the thin filaments. When calcium levels are low within the muscle cell, the troponin complex, including cardiac troponin I, binds to the thin filament. This binding sterically blocks the interaction between the thick and thin filaments that is needed for muscle contraction.
Conversely, when there is an increase in intracellular calcium, calcium ions bind to another component of the troponin complex, troponin C. This binding induces a conformational change in troponin C, which in turn causes the entire troponin complex, including cardiac troponin I, to detach from the thin filament, allowing the heart muscle to contract. Cardiac troponin I's ability to regulate filament interaction is crucial for the heart's rhythmic pump function. Alterations in the function of cardiac troponin I can disrupt this delicate balance, impairing muscle relaxation and overall cardiac performance.
Video: Genetics 101
Chromosome location
The TNNI3 gene is located on chromosome 19, specifically at position 19q13.42. This designation indicates that the gene resides on the long (q) arm of chromosome 19, within region 13, band 42. Humans typically have two copies of chromosome 19, inheriting one from each parent. The precise genomic location of TNNI3 is important for genetic mapping and understanding its physical relationship with other genes in the human genome.
Protein structure
The cardiac troponin I protein, encoded by the TNNI3 gene, consists of 210 amino acids. Its structure includes several functional regions that facilitate its role in regulating cardiac muscle contraction. An N-terminal segment spanning amino acids 1-43 is characterised as a Disordered region. This flexibility may be important for its interactions with other proteins.
A key functional segment, located between amino acids 32 and 79, is Involved in binding TNC (Troponin C). This interaction is critical for calcium-mediated regulation of the troponin complex. Additionally, a region encompassing amino acids 129-149 is Involved in binding TNC and actin, highlighting its dual role in mediating calcium signalling and directly influencing the actin-myosin interaction necessary for muscle contraction.
Key variants
Variants in the TNNI3 gene can occur in various forms, including single nucleotide changes (missense, nonsense) or small insertions or deletions. These genetic alterations can lead to changes in the amino acid sequence of the cardiac troponin I protein, potentially affecting its structure, stability, or ability to interact with other components of the troponin complex or actin filaments. The impact of a specific variant on protein function can range from mild alterations to severe loss of function, which may disrupt the delicate balance required for normal heart muscle contraction and relaxation. The clinical significance of identified TNNI3 variants is typically assessed based on their predicted effect on the protein and correlation with observed cardiac phenotypes.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.575G>A | p.Arg192His | Pathogenic | ★★★☆ | Hypertrophic cardiomyopathy |
c.422G>A | p.Arg141Gln | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.433C>G | p.Arg145Gly | Pathogenic | ★★☆☆ | Hypertrophic cardiomyopathy 7 |
c.433C>T | p.Arg145Trp | Pathogenic | ★★☆☆ | Cardiomyopathy, familial restrictive, 1 |
c.434G>A | p.Arg145Gln | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.470C>T | p.Ala157Val | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.485G>C | p.Arg162Pro | Pathogenic/Likely pathogenic | ★★☆☆ | Hypertrophic cardiomyopathy |
c.497C>T | p.Ser166Phe | Pathogenic/Likely pathogenic | ★★☆☆ | Cardiovascular phenotype |
c.508C>T | p.Arg170Trp | Pathogenic/Likely pathogenic | ★★☆☆ | Restrictive cardiomyopathy |
c.509G>A | p.Arg170Gln | Pathogenic/Likely pathogenic | ★★☆☆ | Cardiovascular phenotype |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the TNNI3 gene are primarily associated with inherited cardiomyopathies, conditions that affect the heart muscle's structure and function. One such condition is familial restrictive cardiomyopathy, characterised by stiffening of the heart muscle walls, which impedes the heart's ability to fill with blood properly [PMID:15682025]. The TNNI3 gene is crucial in regulating heart muscle contraction and relaxation. Variants can impair the cardiac troponin I protein's function, interfering with the overall process. Several mutations in the TNNI3 gene have been identified as causes of familial restrictive cardiomyopathy; these typically involve single amino acid changes that compromise protein function [PMID:15682025].
Inheritance pattern
Conditions caused by pathogenic TNNI3 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
The TNNI3 gene is recognised within the UK's National Health Service (NHS) Genomic Medicine Service pathways, indicating its clinical significance in genetic testing. It is currently listed on several NHS Genomic Test Directories via PanelApp, which reviews and curates gene-disease associations. TNNI3 has a 'green' status, signifying strong evidence for its association with the following conditions: Dilated and arrhythmogenic cardiomyopathy (R132), Dilated Cardiomyopathy and conduction defects, Hypertrophic cardiomyopathy (R131), and Paediatric or syndromic cardiomyopathy (R135). This inclusion highlights TNNI3 as a gene routinely considered in diagnostic investigations for these cardiac conditions within the UK healthcare system.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals with TNNI3-related cardiac conditions, lifestyle management is generally focused on supporting overall cardiovascular health and mitigating disease progression. Research suggests that general heart-healthy behaviours, such as maintaining a balanced diet rich in fruits, vegetables, and whole grains, and limiting saturated fats, trans fats, and sodium, can be beneficial for cardiovascular well-being. Regular, moderate physical activity, as advised by a healthcare professional, can also contribute to heart health. It is often recommended to avoid excessive alcohol consumption and to abstain from smoking, as these factors can place additional strain on the heart. Managing stress through techniques like mindfulness or relaxation can also play a role in overall health. Any lifestyle modifications should always be discussed with a healthcare provider to ensure they are appropriate for an individual's specific condition and health status.
Supplement considerations
There is no conclusive scientific evidence to suggest that specific dietary supplements can prevent, treat, or cure TNNI3-related cardiac conditions. While some supplements are marketed for cardiovascular health, their efficacy in individuals with specific genetic cardiomyopathies is not well-established. It is important to remember that supplements are not regulated with the same stringency as prescription medications. Individuals considering any supplements should consult with their healthcare provider. A doctor or dietitian can offer personalised advice, assess potential interactions with existing medications, and ensure that any dietary changes or supplement use are safe and appropriate for their specific health needs.
Frequently asked questions
What is the TNNI3 gene?
The TNNI3 gene provides instructions for making cardiac troponin I, a protein found exclusively in the heart. It is a crucial component of the troponin complex, which regulates how heart muscle contracts and relaxes.
What does cardiac troponin I do?
Cardiac troponin I helps coordinate the contraction and relaxation of the heart muscle. It acts as an inhibitor, preventing contraction until calcium levels rise, signalling the muscle to contract.
What happens if there's a variant in the TNNI3 gene?
Variants in the TNNI3 gene can alter the cardiac troponin I protein, impairing its function. This can disrupt the normal contraction and relaxation of heart muscle, leading to conditions like familial restrictive cardiomyopathy.
What is restrictive cardiomyopathy?
Restrictive cardiomyopathy is a condition where the heart muscle becomes stiff and less flexible. This makes it difficult for the heart to fill properly with blood between beats, reducing its pumping efficiency.
Is TNNI3 tested in the UK?
Yes, the TNNI3 gene is included in several NHS Genomic Medicine Service panels for cardiac conditions, such as dilated cardiomyopathy and hypertrophic cardiomyopathy, indicating its clinical relevance in the UK.
Can diet or lifestyle influence TNNI3-related conditions?
While diet and lifestyle cannot alter the genetic basis of TNNI3-related conditions, adopting heart-healthy habits, such as a balanced diet and appropriate exercise, can generally support cardiovascular health. Always discuss any lifestyle changes with a healthcare provider.
References
- Marston SB. How do mutations in contractile proteins cause the primary familial cardiomyopathies? Journal of cardiovascular translational research. 2011. PMID: 21424860
- Willott RH, Gomes AV, Chang AN. Mutations in Troponin that cause HCM, DCM AND RCM: what can we learn about thin filament function? Journal of molecular and cellular cardiology. 2010. PMID: 19914256
- Xu Q, Dewey S, Nguyen S. Malignant and benign mutations in familial cardiomyopathies: insights into mutations linked to complex cardiovascular phenotypes. Journal of molecular and cellular cardiology. 2010. PMID: 20298698
- Sen-Chowdhry S, Syrris P, McKenna WJ. Genetics of restrictive cardiomyopathy. Heart failure clinics. 2010. PMID: 20347786
- Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nature clinical practice. Cardiovascular medicine. 2008. PMID: 18227814
- Kaski JP, Syrris P, Burch M. Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart (British Cardiac Society). 2008. PMID: 18467357
- Gomes AV, Liang J, Potter JD. Mutations in human cardiac troponin I that are associated with restrictive cardiomyopathy affect basal ATPase activity and the calcium sensitivity of force development. The Journal of biological chemistry. 2005. PMID: 15961398
- Gomes AV, Potter JD. Cellular and molecular aspects of familial hypertrophic cardiomyopathy caused by mutations in the cardiac troponin I gene. Molecular and cellular biochemistry. 2004. PMID: 15524171
- Bashyam MD, Savithri GR, Kumar MS. Molecular genetics of familial hypertrophic cardiomyopathy (FHC). Journal of human genetics. 2003. PMID: 12601548